Pegfilgrastim and Pegfilgrastim Biosimilars
Customize your policy alerts
Sign up for Arizona Complete Health Policy AZ.CP.PHAR.296 alerts
Get alerted when Policy AZ.CP.PHAR.296 changes without checking for updates manually.
Monitor payer policy activity
This policy governs Arizona Medicaid coverage and prior authorization for pegfilgrastim products used for FDA-approved indications and specified off-label oncology or transplantation uses.
The policy added the pegfilgrastim biosimilar Nyvepria to the policy.
The policy added a requirement to confirm that at least 12 days separate a pegfilgrastim dose from the next chemotherapy cycle.
Preferred colony-stimulating-factor updates made Nyvepria preferred and required Neulasta and Ziextenzo requests to demonstrate failure of Fulphila, Nyvepria, and Udenyca unless contraindicated or clinically significant adverse effects occurred.
The policy removed the requirement for specified Acute Radiation Syndrome and bone marrow transplantation indications to use particular preferred products.
The policy added NCCN Compendium-supported off-label indications.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.